Amino Acid, Peptide, or Protein – Page 46

FDA Approves Bimzelx for Expanded Indications: Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

8 months ago talkbio0Tagged Ankylosing spondylitis, Approved, Arthritis, Psoriatic, Bimzelx, IL-17F inhibitor, IL17A protein, human, non-radiographic axial, Spondylarthritis, United States Food and Drug Administration

Bimzelx, FDA approval, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A and IL-17F inhibitor

Sarclisa Gains FDA Approval as First-Line Treatment for Newly Diagnosed Multiple Myeloma

8 months ago talkbio0Tagged Approved, Combined Modality Therapy, first-line, isatuximab, Multiple Myeloma, sanofi, Sarclisa, United States Food and Drug Administration, VRd

Sarclisa, FDA approval, first-line treatment, multiple myeloma, Sanofi, isatuximab, VRd combination therapy.

FDA Approves AstraZeneca’s FluMist as First Self-Administered Flu Vaccine

8 months ago talkbio0Tagged Approved, AstraZeneca, FluMist, nasal spray vaccine, self-administered flu, United States Food and Drug Administration, Vaccines

FluMist, self-administered flu vaccine, FDA approval, AstraZeneca, nasal spray vaccine

Eli Lilly and Novo Nordisk Support OAC’s Your Weight Matters Campaign Amidst Competitive Weight Loss Drug Market

8 months ago talkbio0Tagged care activity, Drug Industry, Eli, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, OAC, Obesity, Weight-Loss Agents

Eli Lilly, Novo Nordisk, OAC, Your Weight Matters, weight loss drugs, GLP-1, obesity care, pharmaceutical industry

FDA Approves AstraZeneca’s FluMist as First Self-Administered Flu Vaccine

8 months ago talkbio0Tagged accessibility, AstraZeneca, FluMist, nasal spray influenza, self-administered flu, United States Food and Drug Administration, Vaccines

FluMist, AstraZeneca, FDA, self-administered flu vaccine, nasal spray influenza vaccine, flu prevention, influenza disease, vaccine accessibility

Navigating Complex Regulatory Landscapes: The Importance of External Support for Biotech Sponsors in IRB, IBC, DMCs, and EACs

8 months ago talkbio0Tagged 6-aminocaproic acid, Biotech sponsors, Clinical Trials, Clinical Trials Data Monitoring Committees, DMCs, Ethics Advisory Committees, Ethics Committees, Research, gene therapy, IBC, Institutional Biosafety Committee, Regulatory Compliance, research, Risk Management

Biotech sponsors, IRB (Institutional Review Board), IBC (Institutional Biosafety Committee), DMCs (Data Monitoring Committees), EACs (Ethics Advisory Committees), Regulatory compliance, Clinical trials, Gene therapy research, Risk management

Novo Nordisk’s CB1 Drug Monlunabant Shows Weight Loss Potential, but Raises Efficacy and Safety Concerns

8 months ago talkbio0Tagged concerns, Effectiveness, monlunabant, neuropsychiatric side, Nordisk, Obesity, Receptor, Cannabinoid, CB1, Safety

Novo Nordisk, Monlunabant, CB1 receptor, obesity treatment, weight loss, efficacy, safety concerns, neuropsychiatric side effects

Pioneers in Obesity Treatment: Lasker Award Honors Scientists Behind GLP-1 Drugs

8 months ago talkbio0Tagged Glucagon-Like Peptide 1, Habener, Lasker Award, Lotte Bjerre Knudsen, Medical Research activity, Mojsov, Obesity

Lasker Award, GLP-1 drugs, obesity treatment, Joel Habener, Svetlana Mojsov, Lotte Bjerre Knudsen, medical research, pharmaceuticals.

FDA Approves Rybrevant for Third NSCLC Indication This Year

8 months ago talkbio0Tagged Approved, Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, United States Food and Drug Administration

Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment

Theratechnologies Warns of Temporary Supply Disruption for EGRIFTA SV in Early 2025 Due to Third-Party Facility Shutdown

8 months ago talkbio0Tagged Disruption, Egrifta, Facility (object), HIV drug, shutdown, sievert, Theratechnologies

Theratechnologies, EGRIFTA SV, supply disruption, third-party facility shutdown, HIV drug, 2025